CD274 and non-small cell lung carcinoma: In a recent retrospective study of PD-L1-negative, EGFR/ALK wild-type metastatic NSCLC (n=23), BRICS achieved unprecedented efficacy: objective response rate (ORR) 95.7%, median PFS 16.0 months (95% CI: 9.11–22.89), and median OS 32.7 months (95% CI: 11.53–53.87) with minimal toxicity (13).